<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="782" width="593">
	<fontspec id="font0" size="10" family="AdvSMyr-SB" color="#000000"/>
	<fontspec id="font1" size="9" family="AdvC2866" color="#000000"/>
	<fontspec id="font2" size="9" family="AdvC2870" color="#000000"/>
	<fontspec id="font3" size="9" family="AdvTimes" color="#000000"/>
	<fontspec id="font4" size="9" family="AdvP4C4E74" color="#000000"/>
	<fontspec id="font5" size="8" family="AdvPSMy-R" color="#000000"/>
<text top="49" left="45" width="61" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Study Design</text>
<text top="62" left="45" width="243" height="8" font="font1" id="p1_t2" reading_order_no="2" segment_no="3" tag_type="text">The study was a double-blind, 7-d randomized controlled trial</text>
<text top="73" left="45" width="243" height="8" font="font1" id="p1_t3" reading_order_no="3" segment_no="3" tag_type="text">comparing placebo, rofecoxib 50 mg, and diclofenac 150 mg</text>
<text top="84" left="45" width="243" height="8" font="font1" id="p1_t4" reading_order_no="4" segment_no="3" tag_type="text">using a double-dummy technique. The design of the study was</text>
<text top="95" left="45" width="243" height="8" font="font1" id="p1_t5" reading_order_no="5" segment_no="3" tag_type="text">approved by the ethics committee of Cochin Hospital (Paris,</text>
<text top="106" left="45" width="243" height="8" font="font1" id="p1_t6" reading_order_no="6" segment_no="3" tag_type="text">France). All patients gave their written informed consent</text>
<text top="117" left="45" width="243" height="8" font="font1" id="p1_t7" reading_order_no="7" segment_no="3" tag_type="text">before entering the trial. The study was conducted in 47</text>
<text top="128" left="45" width="197" height="8" font="font1" id="p1_t8" reading_order_no="8" segment_no="3" tag_type="text">centers from 15 April 2003 to 16 March 16 2004.</text>
<text top="147" left="45" width="60" height="10" font="font0" id="p1_t9" reading_order_no="9" segment_no="5" tag_type="title">Interventions</text>
<text top="158" left="54" width="51" height="8" font="font2" id="p1_t10" reading_order_no="10" segment_no="6" tag_type="text">Study drugs.</text>
<text top="158" left="108" width="180" height="8" font="font1" id="p1_t11" reading_order_no="11" segment_no="6" tag_type="text">After conﬁrmation of patient eligibility and</text>
<text top="169" left="45" width="243" height="8" font="font1" id="p1_t12" reading_order_no="12" segment_no="6" tag_type="text">after written informed consent was obtained, patients were</text>
<text top="180" left="45" width="243" height="8" font="font1" id="p1_t13" reading_order_no="13" segment_no="6" tag_type="text">randomly assigned to receive placebo, diclofenac 50 mg three</text>
<text top="191" left="45" width="243" height="8" font="font1" id="p1_t14" reading_order_no="14" segment_no="6" tag_type="text">times daily, or rofecoxib 50 mg once daily. All the patients</text>
<text top="203" left="45" width="243" height="8" font="font1" id="p1_t15" reading_order_no="15" segment_no="6" tag_type="text">took four capsules per day (two at breakfast, one at lunch, and</text>
<text top="214" left="45" width="243" height="8" font="font1" id="p1_t16" reading_order_no="16" segment_no="6" tag_type="text">one at dinner) during the seven days of the trial, regardless of</text>
<text top="225" left="45" width="243" height="8" font="font1" id="p1_t17" reading_order_no="17" segment_no="6" tag_type="text">the level of symptoms and the randomization group. Capsules</text>
<text top="236" left="45" width="174" height="8" font="font1" id="p1_t18" reading_order_no="18" segment_no="6" tag_type="text">and packages were identical in appearance.</text>
<text top="247" left="54" width="227" height="8" font="font1" id="p1_t19" reading_order_no="19" segment_no="8" tag_type="text">Compliance was evaluated by pill count at the ﬁnal visit.</text>
<text top="258" left="54" width="71" height="8" font="font2" id="p1_t20" reading_order_no="20" segment_no="9" tag_type="text">Rescue therapies.</text>
<text top="258" left="130" width="158" height="8" font="font1" id="p1_t21" reading_order_no="21" segment_no="9" tag_type="text">Acetaminophen (500 mg tablets, max-</text>
<text top="269" left="45" width="243" height="8" font="font1" id="p1_t22" reading_order_no="22" segment_no="9" tag_type="text">imum eight tablets/day) was used as analgesic treatment</text>
<text top="280" left="45" width="243" height="8" font="font1" id="p1_t23" reading_order_no="23" segment_no="9" tag_type="text">during the study when needed. Since acetaminophen was</text>
<text top="291" left="45" width="243" height="8" font="font1" id="p1_t24" reading_order_no="24" segment_no="9" tag_type="text">supplied as part of the study, a pill count of acetaminophen</text>
<text top="303" left="45" width="112" height="8" font="font1" id="p1_t25" reading_order_no="25" segment_no="9" tag_type="text">was performed at ﬁnal visit.</text>
<text top="314" left="54" width="234" height="8" font="font1" id="p1_t26" reading_order_no="26" segment_no="10" tag_type="text">In cases of persistent intolerable pain, a local injection of</text>
<text top="325" left="45" width="243" height="8" font="font1" id="p1_t27" reading_order_no="27" segment_no="10" tag_type="text">steroids was performed. This injection was deﬁned as treatment</text>
<text top="336" left="45" width="243" height="8" font="font1" id="p1_t28" reading_order_no="28" segment_no="10" tag_type="text">failure, resulting in the withdrawal of the patient from the trial.</text>
<text top="354" left="45" width="47" height="10" font="font0" id="p1_t29" reading_order_no="29" segment_no="12" tag_type="title">Objectives</text>
<text top="367" left="45" width="243" height="8" font="font1" id="p1_t30" reading_order_no="30" segment_no="13" tag_type="text">The objective of this trial was to demonstrate the superiority</text>
<text top="378" left="45" width="243" height="8" font="font1" id="p1_t31" reading_order_no="31" segment_no="13" tag_type="text">of NSAIDs over placebo in acute shoulder pain over a 7-d</text>
<text top="389" left="45" width="71" height="8" font="font1" id="p1_t32" reading_order_no="32" segment_no="13" tag_type="text">treatment period.</text>
<text top="407" left="45" width="46" height="10" font="font0" id="p1_t33" reading_order_no="33" segment_no="15" tag_type="title">Outcomes</text>
<text top="418" left="54" width="109" height="8" font="font2" id="p1_t34" reading_order_no="34" segment_no="16" tag_type="text">Primary outcome measure.</text>
<text top="419" left="167" width="121" height="8" font="font1" id="p1_t35" reading_order_no="35" segment_no="16" tag_type="text">Changes in pain were consid-</text>
<text top="430" left="45" width="243" height="8" font="font1" id="p1_t36" reading_order_no="36" segment_no="16" tag_type="text">ered as the primary outcome measure. The original trial</text>
<text top="441" left="45" width="108" height="8" font="font1" id="p1_t37" reading_order_no="37" segment_no="16" tag_type="text">protocol was referring to a</text>
<text top="440" left="156" width="5" height="8" font="font3" id="p1_t38" reading_order_no="38" segment_no="16" tag_type="text">‘‘</text>
<text top="441" left="160" width="70" height="8" font="font1" id="p1_t39" reading_order_no="39" segment_no="16" tag_type="text">clinically relevant</text>
<text top="440" left="231" width="5" height="8" font="font3" id="p1_t40" reading_order_no="40" segment_no="16" tag_type="text">’’</text>
<text top="441" left="238" width="50" height="8" font="font1" id="p1_t41" reading_order_no="41" segment_no="16" tag_type="text">deﬁnition of</text>
<text top="452" left="45" width="243" height="8" font="font1" id="p1_t42" reading_order_no="42" segment_no="16" tag_type="text">the primary outcome (e.g., a success deﬁned by a sustained</text>
<text top="463" left="45" width="243" height="8" font="font1" id="p1_t43" reading_order_no="43" segment_no="16" tag_type="text">improvement of at least 50% and an absolute level of pain of</text>
<text top="474" left="45" width="243" height="8" font="font1" id="p1_t44" reading_order_no="44" segment_no="16" tag_type="text">30 or less [0–100 normalized scale]). While the recruitment of</text>
<text top="485" left="45" width="243" height="8" font="font1" id="p1_t45" reading_order_no="45" segment_no="16" tag_type="text">patients was still ongoing and based on discussion concerning</text>
<text top="496" left="45" width="243" height="8" font="font1" id="p1_t46" reading_order_no="46" segment_no="16" tag_type="text">the potential loss of statistical power by using a dichotomous</text>
<text top="507" left="45" width="243" height="8" font="font1" id="p1_t47" reading_order_no="47" segment_no="16" tag_type="text">variable instead of a continuous variable, an amendment was</text>
<text top="519" left="45" width="243" height="8" font="font1" id="p1_t48" reading_order_no="48" segment_no="16" tag_type="text">proposed and accepted by the ethical committee to redeﬁne</text>
<text top="530" left="45" width="243" height="8" font="font1" id="p1_t49" reading_order_no="49" segment_no="16" tag_type="text">the primary variable as the mean changes in pain during the</text>
<text top="541" left="45" width="243" height="8" font="font1" id="p1_t50" reading_order_no="50" segment_no="16" tag_type="text">study. Since both techniques resulted in similar ﬁndings, we</text>
<text top="552" left="45" width="243" height="8" font="font1" id="p1_t51" reading_order_no="51" segment_no="16" tag_type="text">are presenting here the results according to the original trial</text>
<text top="563" left="45" width="243" height="8" font="font1" id="p1_t52" reading_order_no="52" segment_no="16" tag_type="text">protocol. For this purpose, a diary was provided to the</text>
<text top="574" left="45" width="243" height="8" font="font1" id="p1_t53" reading_order_no="53" segment_no="16" tag_type="text">patient in order to collect twice a day (in the morning and in</text>
<text top="585" left="45" width="243" height="8" font="font1" id="p1_t54" reading_order_no="54" segment_no="16" tag_type="text">the evening) his/her pain intensity over the 12 previous hours</text>
<text top="596" left="45" width="3" height="8" font="font1" id="p1_t55" reading_order_no="55" segment_no="16" tag_type="text">(</text>
<text top="596" left="48" width="4" height="8" font="font3" id="p1_t56" reading_order_no="56" segment_no="16" tag_type="text">‘‘</text>
<text top="596" left="52" width="39" height="8" font="font1" id="p1_t57" reading_order_no="57" segment_no="16" tag_type="text">nocturnal</text>
<text top="596" left="91" width="5" height="8" font="font3" id="p1_t58" reading_order_no="58" segment_no="16" tag_type="text">’’</text>
<text top="596" left="100" width="145" height="8" font="font1" id="p1_t59" reading_order_no="59" segment_no="16" tag_type="text">pain collected in the morning and</text>
<text top="596" left="250" width="4" height="8" font="font3" id="p1_t60" reading_order_no="60" segment_no="16" tag_type="text">‘‘</text>
<text top="596" left="254" width="29" height="8" font="font1" id="p1_t61" reading_order_no="61" segment_no="16" tag_type="text">diurnal</text>
<text top="596" left="284" width="4" height="8" font="font3" id="p1_t62" reading_order_no="62" segment_no="16" tag_type="text">’’</text>
<text top="607" left="45" width="195" height="8" font="font1" id="p1_t63" reading_order_no="63" segment_no="16" tag_type="text">pain collected in the evening) using a 0–10 NRS.</text>
<text top="618" left="54" width="120" height="8" font="font2" id="p1_t64" reading_order_no="64" segment_no="20" tag_type="text">Secondary outcome measures.</text>
<text top="619" left="177" width="111" height="8" font="font1" id="p1_t65" reading_order_no="65" segment_no="20" tag_type="text">Functional impairment and</text>
<text top="630" left="45" width="243" height="8" font="font1" id="p1_t66" reading_order_no="66" segment_no="20" tag_type="text">patient’s global assessment were considered as secondary</text>
<text top="641" left="45" width="243" height="8" font="font1" id="p1_t67" reading_order_no="67" segment_no="20" tag_type="text">symptomatic outcome measures. Clinical assessment was</text>
<text top="652" left="45" width="243" height="8" font="font1" id="p1_t68" reading_order_no="68" segment_no="20" tag_type="text">performed at baseline and after 7 d by the same investigator,</text>
<text top="663" left="45" width="243" height="8" font="font1" id="p1_t69" reading_order_no="69" segment_no="20" tag_type="text">and functional impairment and patient’s global assessment</text>
<text top="674" left="45" width="243" height="8" font="font1" id="p1_t70" reading_order_no="70" segment_no="20" tag_type="text">were collected. Functional impairment was evaluated using</text>
<text top="685" left="45" width="243" height="8" font="font1" id="p1_t71" reading_order_no="71" segment_no="20" tag_type="text">the function subscale of Neer’s index [21]. This scale consists</text>
<text top="696" left="45" width="243" height="8" font="font1" id="p1_t72" reading_order_no="72" segment_no="20" tag_type="text">of ten questions related to daily activities (1, use back pocket;</text>
<text top="707" left="45" width="243" height="8" font="font1" id="p1_t73" reading_order_no="73" segment_no="20" tag_type="text">2, perineal care; 3, wash opposite axilla; 4, eat with utensil; 5,</text>
<text top="719" left="45" width="243" height="8" font="font1" id="p1_t74" reading_order_no="74" segment_no="20" tag_type="text">comb hair; 6, use hand with arm at shoulder level; 7, carry 10–</text>
<text top="50" left="306" width="243" height="8" font="font1" id="p1_t75" reading_order_no="75" segment_no="2" tag_type="text">15 pounds with arm at side; 8, dress; 9, sleep on side; 10, do</text>
<text top="61" left="306" width="243" height="8" font="font1" id="p1_t76" reading_order_no="76" segment_no="2" tag_type="text">usual work). For each question, a score of 0 was assigned if the</text>
<text top="72" left="306" width="243" height="8" font="font1" id="p1_t77" reading_order_no="77" segment_no="2" tag_type="text">activity could be performed without any difﬁculty, 1 with</text>
<text top="83" left="306" width="243" height="8" font="font1" id="p1_t78" reading_order_no="78" segment_no="2" tag_type="text">some difﬁculty, 2 with marked difﬁculty, 3 with great</text>
<text top="93" left="306" width="243" height="8" font="font1" id="p1_t79" reading_order_no="79" segment_no="2" tag_type="text">difﬁculty (requiring assistance), and 4 if impossible. There-</text>
<text top="104" left="306" width="142" height="8" font="font1" id="p1_t80" reading_order_no="80" segment_no="2" tag_type="text">fore, this scale ranges from 0 to 40.</text>
<text top="115" left="315" width="234" height="8" font="font1" id="p1_t81" reading_order_no="81" segment_no="4" tag_type="text">Patients’ global assessments were evaluated using three</text>
<text top="126" left="306" width="243" height="8" font="font1" id="p1_t82" reading_order_no="82" segment_no="4" tag_type="text">different techniques. In one, at the baseline and the ﬁnal</text>
<text top="137" left="306" width="243" height="8" font="font1" id="p1_t83" reading_order_no="83" segment_no="4" tag_type="text">visits, patient’s global assessment of disease activity was</text>
<text top="148" left="306" width="140" height="8" font="font1" id="p1_t84" reading_order_no="84" segment_no="4" tag_type="text">collected by the following question</text>
<text top="148" left="449" width="4" height="8" font="font3" id="p1_t85" reading_order_no="85" segment_no="4" tag_type="text">‘‘</text>
<text top="148" left="454" width="95" height="8" font="font1" id="p1_t86" reading_order_no="86" segment_no="4" tag_type="text">considering all the ways</text>
<text top="159" left="306" width="243" height="8" font="font1" id="p1_t87" reading_order_no="87" segment_no="4" tag_type="text">your shoulder disease affects you, mark an (X) in the</text>
<text top="170" left="306" width="199" height="8" font="font1" id="p1_t88" reading_order_no="88" segment_no="4" tag_type="text">appropriate box for how well you are doing</text>
<text top="170" left="505" width="5" height="8" font="font3" id="p1_t89" reading_order_no="89" segment_no="4" tag_type="text">’’</text>
<text top="170" left="515" width="34" height="8" font="font1" id="p1_t90" reading_order_no="90" segment_no="4" tag_type="text">and the</text>
<text top="181" left="306" width="243" height="8" font="font1" id="p1_t91" reading_order_no="91" segment_no="4" tag_type="text">following potential answers 0, very well; 1, well; 2, fair; 3,</text>
<text top="192" left="306" width="243" height="8" font="font1" id="p1_t92" reading_order_no="92" segment_no="4" tag_type="text">poor; and 4, very poor. For the analysis, this variable was</text>
<text top="203" left="306" width="217" height="8" font="font1" id="p1_t93" reading_order_no="93" segment_no="4" tag_type="text">considered as a continuous one and normalized from 0</text>
<text top="202" left="525" width="7" height="9" font="font4" id="p1_t94" reading_order_no="94" segment_no="4" tag_type="text">¼</text>
<text top="203" left="533" width="16" height="8" font="font1" id="p1_t95" reading_order_no="95" segment_no="4" tag_type="text">best</text>
<text top="214" left="306" width="67" height="8" font="font1" id="p1_t96" reading_order_no="96" segment_no="4" tag_type="text">condition to 100</text>
<text top="213" left="375" width="7" height="9" font="font4" id="p1_t97" reading_order_no="97" segment_no="4" tag_type="text">¼</text>
<text top="214" left="384" width="65" height="8" font="font1" id="p1_t98" reading_order_no="98" segment_no="4" tag_type="text">worst condition.</text>
<text top="225" left="315" width="234" height="8" font="font1" id="p1_t99" reading_order_no="99" segment_no="7" tag_type="text">In a second technique, at the ﬁnal visit, patient’s global</text>
<text top="236" left="306" width="243" height="8" font="font1" id="p1_t100" reading_order_no="100" segment_no="7" tag_type="text">assessment on her/his relative condition was collected by the</text>
<text top="247" left="306" width="75" height="8" font="font1" id="p1_t101" reading_order_no="101" segment_no="7" tag_type="text">following question:</text>
<text top="246" left="384" width="4" height="8" font="font3" id="p1_t102" reading_order_no="102" segment_no="7" tag_type="text">‘‘</text>
<text top="247" left="388" width="161" height="8" font="font1" id="p1_t103" reading_order_no="103" segment_no="7" tag_type="text">compared to when you started the study,</text>
<text top="258" left="306" width="200" height="8" font="font1" id="p1_t104" reading_order_no="104" segment_no="7" tag_type="text">how have you been during the last 48 hours?</text>
<text top="257" left="506" width="4" height="8" font="font3" id="p1_t105" reading_order_no="105" segment_no="7" tag_type="text">’’</text>
<text top="258" left="516" width="33" height="8" font="font1" id="p1_t106" reading_order_no="106" segment_no="7" tag_type="text">and the</text>
<text top="269" left="306" width="143" height="8" font="font1" id="p1_t107" reading_order_no="107" segment_no="7" tag_type="text">following potential 15 answers from</text>
<text top="269" left="456" width="93" height="8" font="font1" id="p1_t108" reading_order_no="108" segment_no="7" tag_type="text">7, very great deal worse</text>
<text top="280" left="306" width="8" height="8" font="font1" id="p1_t109" reading_order_no="109" segment_no="7" tag_type="text">to</text>
<text top="279" left="316" width="7" height="9" font="font4" id="p1_t110" reading_order_no="110" segment_no="7" tag_type="text">þ</text>
<text top="280" left="322" width="227" height="8" font="font1" id="p1_t111" reading_order_no="111" segment_no="7" tag_type="text">7, very great deal better. For the analysis, we considered</text>
<text top="291" left="306" width="243" height="8" font="font1" id="p1_t112" reading_order_no="112" segment_no="7" tag_type="text">this variable as a dichotomous one (e.g., improvement yes/no</text>
<text top="302" left="306" width="243" height="8" font="font1" id="p1_t113" reading_order_no="113" segment_no="7" tag_type="text">in which an improvement was considered for the patients</text>
<text top="313" left="306" width="71" height="8" font="font1" id="p1_t114" reading_order_no="114" segment_no="7" tag_type="text">answering at least</text>
<text top="312" left="380" width="4" height="8" font="font3" id="p1_t115" reading_order_no="115" segment_no="7" tag_type="text">‘‘</text>
<text top="313" left="385" width="66" height="8" font="font1" id="p1_t116" reading_order_no="116" segment_no="7" tag_type="text">good deal better</text>
<text top="312" left="451" width="4" height="8" font="font3" id="p1_t117" reading_order_no="117" segment_no="7" tag_type="text">’’</text>
<text top="313" left="455" width="5" height="8" font="font1" id="p1_t118" reading_order_no="118" segment_no="7" tag_type="text">).</text>
<text top="324" left="315" width="234" height="8" font="font1" id="p1_t119" reading_order_no="119" segment_no="11" tag_type="text">In a third technique, at the ﬁnal visit, acceptable symptom</text>
<text top="335" left="306" width="187" height="8" font="font1" id="p1_t120" reading_order_no="120" segment_no="11" tag_type="text">state was assessed by the following question:</text>
<text top="334" left="498" width="5" height="8" font="font3" id="p1_t121" reading_order_no="121" segment_no="11" tag_type="text">‘‘</text>
<text top="335" left="502" width="46" height="8" font="font1" id="p1_t122" reading_order_no="122" segment_no="11" tag_type="text">considering</text>
<text top="346" left="306" width="243" height="8" font="font1" id="p1_t123" reading_order_no="123" segment_no="11" tag_type="text">your current level of pain and functional impairment, if you</text>
<text top="356" left="306" width="243" height="8" font="font1" id="p1_t124" reading_order_no="124" segment_no="11" tag_type="text">were to remain for the next following months as you were</text>
<text top="367" left="306" width="243" height="8" font="font1" id="p1_t125" reading_order_no="125" segment_no="11" tag_type="text">during the last 48 hours would this be acceptable or</text>
<text top="378" left="306" width="87" height="8" font="font1" id="p1_t126" reading_order_no="126" segment_no="11" tag_type="text">unacceptable to you?</text>
<text top="378" left="393" width="4" height="8" font="font3" id="p1_t127" reading_order_no="127" segment_no="11" tag_type="text">’’</text>
<text top="378" left="401" width="148" height="8" font="font1" id="p1_t128" reading_order_no="128" segment_no="11" tag_type="text">and the potential following answers</text>
<text top="389" left="306" width="127" height="8" font="font1" id="p1_t129" reading_order_no="129" segment_no="11" tag_type="text">0, acceptable; 1, not acceptable.</text>
<text top="400" left="315" width="234" height="8" font="font1" id="p1_t130" reading_order_no="130" segment_no="14" tag_type="text">Moreover, the requirement for rescue therapies (e.g.,</text>
<text top="411" left="306" width="243" height="8" font="font1" id="p1_t131" reading_order_no="131" segment_no="14" tag_type="text">acetaminophen intake and/or local injection of steroids) was</text>
<text top="422" left="306" width="242" height="8" font="font1" id="p1_t132" reading_order_no="132" segment_no="14" tag_type="text">also considered as a secondary outcome measure of efﬁcacy.</text>
<text top="433" left="315" width="234" height="8" font="font1" id="p1_t133" reading_order_no="133" segment_no="17" tag_type="text">At baseline and ﬁnal visit, blood pressure and body weight</text>
<text top="444" left="306" width="243" height="8" font="font1" id="p1_t134" reading_order_no="134" segment_no="17" tag_type="text">were systematically collected and at ﬁnal visit, the inves-</text>
<text top="455" left="306" width="129" height="8" font="font1" id="p1_t135" reading_order_no="135" segment_no="17" tag_type="text">tigators checked for tolerability.</text>
<text top="470" left="306" width="55" height="10" font="font0" id="p1_t136" reading_order_no="136" segment_no="18" tag_type="title">Sample Size</text>
<text top="483" left="306" width="243" height="8" font="font1" id="p1_t137" reading_order_no="137" segment_no="19" tag_type="text">The sample size needed in order to demonstrate a statistically</text>
<text top="494" left="306" width="243" height="8" font="font1" id="p1_t138" reading_order_no="138" segment_no="19" tag_type="text">signiﬁcant difference between NSAID and placebo using the</text>
<text top="505" left="306" width="243" height="8" font="font1" id="p1_t139" reading_order_no="139" segment_no="19" tag_type="text">pain intensity (mean of nocturnal and diurnal pain) was</text>
<text top="516" left="306" width="243" height="8" font="font1" id="p1_t140" reading_order_no="140" segment_no="19" tag_type="text">calculated. A success was a priori deﬁned by a sustained</text>
<text top="527" left="306" width="243" height="8" font="font1" id="p1_t141" reading_order_no="141" segment_no="19" tag_type="text">improvement of at least 50% and an absolute level of pain 30</text>
<text top="538" left="306" width="243" height="8" font="font1" id="p1_t142" reading_order_no="142" segment_no="19" tag_type="text">or less (on a 0–100 normalized scale). The analysis was</text>
<text top="549" left="306" width="243" height="8" font="font1" id="p1_t143" reading_order_no="143" segment_no="19" tag_type="text">conducted using the Kaplan-Meier technique in which the</text>
<text top="559" left="306" width="243" height="8" font="font1" id="p1_t144" reading_order_no="144" segment_no="19" tag_type="text">event was deﬁned by the time the patient fulﬁlled the above</text>
<text top="570" left="306" width="243" height="8" font="font1" id="p1_t145" reading_order_no="145" segment_no="19" tag_type="text">deﬁnition of improvement in pain with such an improvement</text>
<text top="581" left="306" width="243" height="8" font="font1" id="p1_t146" reading_order_no="146" segment_no="19" tag_type="text">sustained until the end of the study. Based on information on</text>
<text top="592" left="306" width="243" height="8" font="font1" id="p1_t147" reading_order_no="147" segment_no="19" tag_type="text">changes in pain in previously reported trials [22], the Kaplan-</text>
<text top="603" left="306" width="243" height="8" font="font1" id="p1_t148" reading_order_no="148" segment_no="19" tag_type="text">Meier estimates of the percentage of patients achieving such</text>
<text top="614" left="306" width="243" height="8" font="font1" id="p1_t149" reading_order_no="149" segment_no="19" tag_type="text">an improvement was expected to be around 40% in the active</text>
<text top="625" left="306" width="243" height="8" font="font1" id="p1_t150" reading_order_no="150" segment_no="19" tag_type="text">group. Since, to our knowledge, no information was available</text>
<text top="636" left="306" width="243" height="8" font="font1" id="p1_t151" reading_order_no="151" segment_no="19" tag_type="text">in the literature concerning the placebo group, we a priori</text>
<text top="647" left="306" width="243" height="8" font="font1" id="p1_t152" reading_order_no="152" segment_no="19" tag_type="text">and arbitrarily expected a 20% success rate in the placebo</text>
<text top="658" left="306" width="243" height="8" font="font1" id="p1_t153" reading_order_no="153" segment_no="19" tag_type="text">group. Thus a sample size of 82 patients per treatment group</text>
<text top="669" left="306" width="243" height="8" font="font1" id="p1_t154" reading_order_no="154" segment_no="19" tag_type="text">would allow demonstration of this difference with an alpha</text>
<text top="680" left="306" width="171" height="8" font="font1" id="p1_t155" reading_order_no="155" segment_no="19" tag_type="text">level of 0.05 and power of 0.80 two-tailed).</text>
<text top="695" left="306" width="172" height="10" font="font0" id="p1_t156" reading_order_no="156" segment_no="21" tag_type="title">Randomization: Sequence Generation</text>
<text top="708" left="306" width="243" height="8" font="font1" id="p1_t157" reading_order_no="157" segment_no="22" tag_type="text">A computer-generated randomization sequence assigned</text>
<text top="719" left="306" width="243" height="8" font="font1" id="p1_t158" reading_order_no="158" segment_no="22" tag_type="text">participants in a 1:1:1 ratio to receive rofecoxib, diclofenac,</text>
<text top="742" left="45" width="85" height="7" font="font5" id="p1_t159" reading_order_no="159" segment_no="23" tag_type="text">www.plosclinicaltrials.org</text>
<text top="742" left="490" width="59" height="7" font="font5" id="p1_t160" reading_order_no="161" segment_no="24" tag_type="text">March | 2007 | e9</text>
<text top="742" left="289" width="16" height="7" font="font5" id="p1_t161" reading_order_no="160" segment_no="25" tag_type="text">0003</text>
<text top="26" left="401" width="148" height="7" font="font5" id="p1_t162" reading_order_no="0" segment_no="0" tag_type="title">NSAID Treatment in Rotator Cuff Syndrome</text>
</page>
</pdf2xml>
